Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Clin Oncol (R Coll Radiol). 2012 Dec;24(10):684-96. doi: 10.1016/j.clon.2012.04.005. Epub 2012 May 18.
Hormone receptor testing (oestrogen and progesterone) in breast cancer at the time of primary diagnosis is used to guide treatment decisions. Accurate and standardised testing methods are critical to ensure the proper classification of the patient's hormone receptor status. Recommendations were developed to improve the quality and accuracy of hormone receptor testing based on a systematic review conducted jointly by the American Society of Clinical Oncology/College of American Pathologists and Cancer Care Ontario's Program in Evidence-Based Care. Evidence-based recommendations were formulated to set standards for optimising immunohistochemistry in assessing hormone receptor status, as well as assuring quality and proficiency between and within laboratories. A formal external review was conducted to validate the relevance of these recommendations. It is anticipated that widespread adoption of these guidelines will further improve the accuracy of hormone receptor testing in Canada.
在原发性乳腺癌诊断时进行激素受体检测（雌激素和孕激素），用于指导治疗决策。准确和标准化的检测方法对于确保患者激素受体状态的正确分类至关重要。这些建议是基于美国临床肿瘤学会/美国病理学家学院和安大略省癌症护理证据基础护理计划联合进行的系统审查制定的，旨在提高激素受体检测的质量和准确性。制定了循证建议，为优化免疫组织化学评估激素受体状态设定了标准，并确保了实验室之间和内部的质量和熟练度。进行了正式的外部审查，以验证这些建议的相关性。预计这些指南的广泛采用将进一步提高加拿大激素受体检测的准确性。
